Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex
Starmer’s China Visit Signals New Era in UK–China Economic Relations
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars
Google Halts UK YouTube TV Measurement Service After Legal Action
Asian Currencies Slip as Dollar Rebounds Ahead of Fed Rate Decision
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation
Dollar Slumps to Four-Year Lows as Trump Shrugs Off Weakness, Fueling Confidence Crisis
UK Vehicle Production Falls Sharply in 2025 Amid Cyberattack, Tariffs, and Industry Restructuring
RBA Expected to Raise Interest Rates by 25 Basis Points in February, ANZ Forecast Says
Australia Wine Exports Fall in 2025 as Global Drinking Declines and China Demand Weakens
ASML’s EUV Monopoly Powers the Global AI Chip Boom
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results
U.S. and Taiwan Strengthen AI, Semiconductor, and Drone Cooperation at High-Level Economic Talks
Asian Currencies Trade Flat as Dollar Retreats After Fed Decision
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 



